Hologic, Inc. announced that the U.S. Food and Drug Administration has approved its Aptima® HPV Assay for clinician‑collected primary screening of cervical cancer, adding a new indication to the company’s existing Pap‑plus‑HPV co‑testing and Pap‑only offerings.
The Aptima assay is the only FDA‑approved mRNA‑based HPV test, detecting E6/E7 messenger RNA that signals biologically active infections more likely to progress to precancerous lesions. A real‑world evidence study of more than 650,000 women showed that the assay’s sensitivity for CIN2+ and CIN3+ lesions is clinically comparable to the leading DNA‑based HPV tests, giving Hologic a technical edge in a market that is increasingly moving toward primary HPV screening.
The approval expands Hologic’s cervical health portfolio and positions the company as a technology leader in a rapidly evolving screening landscape. By adding a primary screening indication, Hologic can offer clinicians greater flexibility, potentially increasing test volumes across its laboratory and point‑of‑care platforms and capturing a larger share of the growing primary HPV market. Management noted that the mRNA approach may improve specificity without compromising sensitivity, aligning with updated guidelines from the U.S. Preventive Services Task Force.
Hologic’s Q4 2025 results provide context for the approval’s financial impact. The company reported non‑GAAP diluted earnings per share of $1.13, beating the consensus estimate of $1.10 by $0.03, and revenue of $1.049 billion, slightly above the $1.030 billion estimate. The earnings beat was driven by disciplined cost management and a favorable mix of high‑margin diagnostic services, while the revenue beat reflected strong demand for women’s health diagnostics amid a competitive landscape. CEO and President of Diagnostic Solutions Jennifer Schneiders said the approval “reflects our ongoing commitment to advancing women’s health through innovative, evidence‑based solutions” and that the new indication would “provide providers with more choice and flexibility.”
The approval comes as Hologic is in the final stages of a definitive acquisition agreement with funds managed by Blackstone and TPG. Because the company is not providing new financial guidance for fiscal year 2026, the approval is viewed as a strategic win that enhances the value of the diagnostics business and supports the broader acquisition narrative.
The FDA approval is expected to strengthen Hologic’s market position, drive incremental revenue from increased test volumes, and reinforce the company’s reputation as a leader in mRNA‑based diagnostics. The move also aligns with industry trends toward primary HPV screening and positions Hologic to capture a larger share of the cervical cancer screening market as guidelines evolve.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.